Stéphane Budel, founding partner at DeciBio, joins the Talking Precision Medicine Podcast to explore the future of the field. He unpacks how liquid biopsy, multi-omics, and AI are opening new doors for personalized care, why the diagnostics business model is holding innovation back, and what it will take to make complex tech usable for clinicians and patients alike.

⁠TPM E46 highlights >⁠⁠⁠⁠⁠⁠⁠⁠

Episode 46 links:

• DeciBio

• Stephane Budel on LinkedIn

DeciBio’s White Paper on AI in Drug Development (with contributions from Rafael Rosengarten)